Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
al, allege, Amber, announce, announced, announcement, asserted, bringing, captioned, Carlisle, cleared, complaint, conference, consent, constituting, decline, Delaware, Diebolt, dispose, district, Eastern, encumber, England, enjoin, expressly, federal, Fennec, fire, foregoing, frame, futility, Guarantor, hurdle, immunotherapy, incomplete, inquiry, instituted, invoX, Jacob, linear, live, merger, merit, mid, minute, misleading, organizational, Parent, pendency, people, Pharma, pledge, preserve, promote, promulgated, proof, proposed, pursuit, ratably, repurchase, respond, responding, Sam, settle, Sino, Solicitation, Southern, superior, surviving, Takeda, tender, thereunder, tied, timeframe, turn, unvested, USA, variety, waived, Wheeler, withholding, York
Removed:
dedicated, intention, PK, proportional, referred, rental, transform
Filing tables
Filing exhibits
FSTX similar filings
Filing view
External links
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of F-star Therapeutics, Inc. (the “Company”) on Form 10-Q for the period ending June 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
Date: August 11, 2022 |
| By: | /s/ Eliot R. Forster |
|
|
| Eliot R. Forster, Ph.D. |
|
|
| President and Chief Executive Officer |